BlackRock Advisors’s AstraZeneca AZN Stock Holding History

BlackRock Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.5M	Sell	64,000 -1,014,863	-94%	-$57.6M	﹤0.01%	1279
2016 Q3	$70.9M	Buy	1,078,863 +1,014,863	+1,586%	+$66.3M	0.07%	267
2016 Q2	$3.86M	Hold	64,000	–	–	﹤0.01%	1209
2016 Q1	$3.6M	Sell	64,000 -87,303	-58%	-$5.25M	﹤0.01%	1216
2015 Q4	$10.3M	Sell	151,303 -650,175	-81%	-$42.6M	0.01%	816
2015 Q3	$51M	Sell	801,478 -572,668	-42%	-$37.7M	0.05%	298
2015 Q2	$87.5M	Sell	1,374,146 -51,225	-4%	-$3.51M	0.09%	216
2015 Q1	$97.5M	Buy	1,425,371 +126,545	+10%	+$8.79M	0.1%	216
2014 Q4	$91.4M	Buy	1,298,826 +738,220	+132%	+$52.9M	0.09%	234
2014 Q3	$40M	Sell	560,606 -4,606	-0.8%	-$337K	0.04%	394
2014 Q2	$42M	Sell	565,212 -1,522,996	-73%	-$110M	0.04%	395
2014 Q1	$135M	Sell	2,088,208 -76,292	-4%	-$4.93M	0.13%	181
2013 Q4	$129M	Buy	2,164,500 +829,800	+62%	+$45.1M	0.12%	192
2013 Q3	$69.3M	Buy	1,334,700 +338,600	+34%	+$17M	0.07%	279
2013 Q2	$47.1M	Buy	+996,100	New	+$50.7M	0.05%	326

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BlackRock Advisors's AZN Position: Q4 2016 in Review

BlackRock Advisors reduced its AstraZeneca (AZN) stake by 94% in Q4 2016, selling an estimated $57.6M and leaving 64,000 shares worth $3.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1279.

BlackRock Advisors first reported a position in AZN in Q2 2013 and has held it in 15 quarters since. The position peaked at $135M in Q1 2014. 450 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

BlackRock Advisors held 64,000 shares of AstraZeneca worth $3.5M as of Q4 2016.
BlackRock Advisors sold 1,014,863 AstraZeneca shares in Q4 2016, an estimated $57.6M.
AstraZeneca made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1279 holding.
BlackRock Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's AstraZeneca position peaked at $135M in Q1 2014.
450 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.